Genialis develops next-generation patient classifiers
Redapine portfolio company Genialis (RACIII) is one step closer to achieving its mission to outsmart cancer. The company has received over $13 million in Series A funding led by Taiwania Capital and Debiopharm Innovation Fund, with participation from previous investors First Star Ventures and Pikas, as well as new investors P5 Health Ventures and several angels. We’re delighted to contribute to this investment and to provide strategic guidance to the Genialis team as the company grows.
Using machine learning and high-throughput-omics data, Genialis develops next-generation patient classifiers that capture underlying disease biology and predict how patients are likely to respond to targeted therapies. With the new funding, they plan to expand their proprietary ResponderID™ platform and build out their collection of clinically validated biomarker models to provide pinpoint diagnoses for virtually every cancer patient.
The team at Genialis is committed to serving researchers who use their platform to push the boundaries of what's possible in precision medicine. The company will also invest in expanding the team in the U.S. and Europe and in R&D collaborations with several leading cancer centers, hospital groups, and clinical academic labs.
We have been a proud supporter of Genialis since we led their seed funding round in 2017, and we can't wait to see how they will continue to transform the world of precision medicine. Congratulations to the team!